Atwater Malick LLC Has $341,000 Stake in Danaher Corporation $DHR

Atwater Malick LLC grew its stake in shares of Danaher Corporation (NYSE:DHR) by 8.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,724 shares of the conglomerate’s stock after buying an additional 127 shares during the period. Atwater Malick LLC’s holdings in Danaher were worth $341,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in Danaher by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock worth $12,296,123,000 after acquiring an additional 230,966 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Danaher by 3.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock worth $4,016,404,000 after purchasing an additional 612,154 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Danaher by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate’s stock worth $1,800,614,000 after purchasing an additional 194,466 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after buying an additional 1,450,703 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Danaher by 4.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate’s stock valued at $867,168,000 after buying an additional 163,332 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on DHR. Scotiabank upgraded Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 target price on the stock in a report on Friday, July 11th. UBS Group cut their price objective on Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a report on Wednesday, July 23rd. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research note on Friday, June 27th. Guggenheim reaffirmed a “buy” rating and issued a $250.00 price target on shares of Danaher in a research note on Wednesday, July 23rd. Finally, Evercore ISI reduced their price target on shares of Danaher from $230.00 to $226.00 and set an “outperform” rating for the company in a report on Tuesday, July 8th. Seventeen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $245.91.

Danaher Trading Down 1.1%

Shares of NYSE:DHR opened at $210.64 on Friday. The company’s 50-day moving average price is $200.00 and its two-hundred day moving average price is $197.40. Danaher Corporation has a one year low of $171.00 and a one year high of $279.41. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The stock has a market capitalization of $150.83 billion, a PE ratio of 44.82, a price-to-earnings-growth ratio of 3.03 and a beta of 0.77.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same quarter in the previous year, the business earned $1.72 earnings per share. Danaher’s quarterly revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a dividend of $0.32 per share. The ex-dividend date is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s dividend payout ratio is currently 27.23%.

Insider Activity at Danaher

In related news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.